ProQR Therapeutics appointed Chris Hart as chief data and AI officer and Thomas Wolf as a strategic AI advisor to its board, with AX-0811 target engagement data expected in early January 2027. ProQR says the appointments support its plan to scale artificial intelligence across medicine discovery and development.
Key Highlights
- Chris Hart, PhD, has been appointed ProQR’s chief data and AI officer.
- Thomas Wolf, PhD, will join ProQR’s Board of Directors as a strategic AI advisor.
- ProQR expects AX-0811 target engagement data in early January 2027.
ProQR Therapeutics N.V. (NASDAQ: PRQR) is a Pharmaceuticals: Major company. Chris Hart has been appointed chief data and AI officer, while Thomas Wolf is set to join the Board of Directors as a strategic AI advisor.
ProQR Adds Hart and Wolf to AI Leadership
Nvidia (NASDAQ: NVDA) has recently agreed to acquire Hugging Face. The appointments concern both management and board-level strategic advice. ProQR said the pair bring complementary expertise relevant to integrating artificial intelligence into drug discovery and development.
AX-0811 Marks First AI-Enabled Clinical Program
The company described AX-0811 as its first program identified through its AI-enabled discovery engine to reach clinical testing. The stated development plan includes target engagement data for AX-0811 in early January 2027. ProQR also said its expanded AI strategy is directly supporting ongoing development programs.
FAQs
Q: Who is ProQR Therapeutics’ new chief data and AI officer?
A: Chris Hart has been appointed ProQR Therapeutics’ chief data and AI officer. The article does not state his academic credentials or previous employer.
Q: Who will serve as ProQR’s strategic AI advisor?
A: Thomas Wolf, PhD, will join ProQR Therapeutics’ Board of Directors as a strategic AI advisor. He is co-founder and Chief Science Officer of Hugging Face.
Q: When does ProQR expect AX-0811 target engagement data?
A: ProQR expects target engagement data for AX-0811 in early January 2027. The company described AX-0811 as its first program identified through its AI-enabled discovery engine to reach clinical testing.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.